In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovirdipivoxil-resistant HBV mutations

Antiviral Therapy

Volumn 17, Issue 5, 2012, Pages 793-803

  Wang, Xue Yan ^a,b   Wei, Zhen Man ^c   Wu, Guo Yi ^a   Wang, Jiang Hua ^a   Zhang, Ying Jun ^d   Li, Jing ^d   Zhang, Heng Hui ^a   Xie, Xing Wang ^a   Wang, Xian ^d   Wang, Zhao He ^d   Wei, Lai ^a   Wang, Yu ^e   Chen, Hong Song ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b BEIHUA UNIVERSITY   (China)

^c BEIJING 302 HOSPITAL   (China)

^d Sunshine Lake Pharma Co Ltd   (China)

^e CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; CAPSID PROTEIN; CORE PROTEIN; ETHYL 4 (2 BROMO 4 FLUOROPHENYL) 6 (MORPHOLINOMETHYL) 2 (2 THIAZOLYL) 1,4 DIHYDROPYRIMIDINE 5 CARBOXYLATE; GLS 4; LAMIVUDINE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS DNA;

ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG STRUCTURE; ELECTRON MICROSCOPY; HEPATITIS B VIRUS; IC 50; IMMUNOBLOTTING; IN VITRO STUDY; LIGHT SCATTERING; NONHUMAN; PRIORITY JOURNAL; SOUTHERN BLOTTING; VIRUS INHIBITION; VIRUS MUTANT; VIRUS MUTATION; VIRUS STRAIN;

ADENINE; ANTIVIRAL AGENTS; CAPSID PROTEINS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HEP G2 CELLS; HEPATITIS B VIRUS; HUMANS; INHIBITORY CONCENTRATION 50; MUTATION; ORGANOPHOSPHONATES; VIRAL CORE PROTEINS; VIRUS ASSEMBLY; VIRUS REPLICATION;

EID: 84865773658     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2152     Document Type: Article

References (30)

1. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64:51-68.
2. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000-summary of a workshop. Gastroenterology 2001; 120:1828-1853.
3. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg negative chronic hepatitis B. N Engl J Med 2004; 351:1206-1217.
4. Doong SL, Tsai CH, Schinazi RF, et al. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991; 88:8495-8499.
5. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348:808-816.
6. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354:1001-1010.
7. Jones R, Nelson M. Novel anti-hepatitis B agents: a focus on telbivudine. Int J Clin Pract 2006; 60:1295-1299.
8. Lacombe K, Gozlan J, Boelle PY, et al. Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate. AIDS 2005; 19:907-915.
9. De Clercq E. Perspectives for the treatment of hepatitis B virus infections. Int J Antimicrob Agents 1999; 12:81-95.
10. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373:582-592.
11. Zlotnick A, Stray SJ. How does your virus grow? Understanding and interfering with virus assembly. Trends Biotechnol 2003; 21:536-542.
12. Weber O, Schlemmer KH, Hartmann E, et al. Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model. Antiviral Res 2002; 54:69-78.
13. Deres K, Schröder CH, Paessens A, et al. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 2003; 299:893-896.
14. Wang Y, Wei L, Jiang D, et al. In vitro resistance to interferon of hepatitis B virus with precore mutation. World J Gastroenterol 2005; 11:649-655.
15. Wang JH, Li JQ, Jiang D, et al. The construction of HBV strains with rt181V/T mutations associated with resistance to adefovir and its viral characteristics. Chinese Journal of Laboratory Medicine 2007; 30:1035-1039.
16. Sells MA, Chen ML, Acs G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci U S A 1987; 84:1005-1009.
17. Knowles BB, Howe CC, Aden DP. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 1980; 209:497-499.
18. Kann M, Sodeik B, Vlachou A, et al. Phosphorylation-dependent binding of hepatitis B virus core particles to the nuclear pore complex. J Cell Biol 1999; 145:45-55.
19. Zlotnick A, Cheng N, Conway JF, et al. Dimorphism of hepatitis B virus capsids is strongly influenced by the C-terminus of the capsid protein. Biochemistry 1996; 35:7412-7421.
20. Zlotnick A, Ceres P, Singh S, et al. A small molecule inhibits and misdirects assembly of hepatitis B virus capsids. J Virol 2002; 76:4848-4854.
21. Wynne SA, Crowther RA, Leslie AG. The crystal structure of the human hepatitis B virus capsid. Mol Cell 1999; 3:771-780.
22. Kenney JM, von Bonsdorff CH, Nassal M, et al. Evolutionary conservation in the hepatitis B virus core structure: comparison of human and duck cores. Structure 1995; 3:1009-1019.
23. Crowther RA, Kiselev NA, Böttcher B, et al. Three-dimensional structure of hepatitis B virus core particles determined by electron cryomicroscopy. Cell 1994; 77:943-950.
24. Zhou S, Standring DN. Hepatitis B virus capsid particles are assembled from core-protein dimer precursors. Proc Natl Acad Sci U S A 1992; 89:10046-10050.
25. Zlotnick A, Johnson JM, Wingfield PW, et al. A theoretical model successfully identifies features of hepatitis B virus capsid assembly. Biochemistry 1999; 38:14644-14652.
26. Ceres P, Zlotnick A. Weak protein-protein interactions are sufficient to drive assembly of hepatitis B virus capsids. Biochemistry 2002; 41:11525-11531.
27. Hacker HJ, Deres K, Mildenberger M, et al. Antivirals interacting with hepatitis B virus core protein and core mutations may misdirect capsid assembly in a similar fashion. Biochem Pharmacol 2003; 66:2273-2279.
28. Stray SJ, Zlotnick A. BAY 41-4109 has multiple effects on Hepatitis B virus capsid assembly. J Mol Recognit 2006; 19:542-548.
29. Wu GY, Zheng XJ, Yin CC, et al. Inhibition of hepatitis B virus replication by Bay 41-4109 and its association with nucleocapsid disassembly. J Chemother 2008; 20:458-467.
30. Zlotnick A. Are weak protein-protein interactions the general rule in capsid assembly? Virology 2003; 315:269-274.